A Phase IIa, Randomised, Double-blind, Placebo-controlled Outpatients Study to Investigate the Duration of Effect and Safety of PrEP-001 Given Prophylactically in Healthy Subjects, Subsequently Challenged With Human Rhinovirus (HRV-16)
Latest Information Update: 19 Mar 2019
Price :
$35 *
At a glance
- Drugs Poly ICLC (Primary)
- Indications Influenza virus infections
- Focus Therapeutic Use
- Sponsors PrEP Biopharm
- 19 Mar 2019 New source identified and integrated as European Clinical Trials Database (EudraCT2015-005492-25 )
- 15 Nov 2017 New trial record